Home About Company Overview Management The Board R&D Research Focus CRTH2 Biology Patients OC459 Clinical Pressroom Press Releases Publications Presentations Contact Atopix Therapeutics Limited is a clinical stage biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma OC459 is a low dose, once-a-day drug with an excellent safety profile in over 800 patients and evidence of efficacy in patients with eosinophilic asthma CRTH2 receptor and its role in allergy It is increasingly recognised that anti-TH2 therapies will find a place in the treatment of atopic dermatitis © 2015 Atopix Therapeutics Ltd Identity by Franks and Franks